Error loading player: No playable sources found

89826

Plenary Session 5 - Stem Cell-derived Medicinal Products

Date
June 12, 2024
This product is not available for individual purchase, but it is available as part of the following products:

Stem cell-derived medicines have seen somewhat of a renaissance over the last year, following a difficult period in terms of regulatory approval. New stem cell therapies, including many iPSC-based therapies, are now under development for a variety of indications and more traditional regenerative approaches have seen regulatory approval. Despite this, there remain difficult challenges for stem cell-derived products, including product characterization and potency assay development for mechanisms of action that often must be postulated fairly widely.  

This session will present case studies by stakeholders that are successfully navigating this field, together with viewpoints from regulators.  


Speaker:


Releasing Criteria and Potency Assay Development of an iPSC-Derived Neural Progenitor Cell Product Targeting CNS Diseases

Jing Fan, Hopstem Biotechnology Inc.


Navigating the Regulatory Path: Clinical Translation of iPSCs 

Saravanan Karumbayaram, CBER, FDA


Cellular Engineering to Address Manufacturing and Regulatory Concerns

Todd McDevittGenentech, a Member of the Roche Group



Panelist:


Andreea Barbu, Swedish Medical Products Agency


Related Products

Thumbnail for Parallel Session 3 - Viral Vector-based Gene Therapy Products
Parallel Session 3 - Viral Vector-based Gene Therapy Products
The field of Cell and Gene Therapy has witnessed expanding numbers of regulatory approvals in recent years…
Thumbnail for Plenary Session 8 - Global Regulatory Updates and Panel Discussion & Closing Remarks
Plenary Session 8 - Global Regulatory Updates and Panel Discussion & Closing Remarks
The cell and gene therapy field spans an enormous range of product types and technologies with the potential to provide curative treatments for a wide range of serious diseases…
Thumbnail for Plenary Session 7 - Streamlining AAV Vector-based Gene Therapy Development Through the Utilization of Manufacturing and Analytical Platform Approaches
Plenary Session 7 - Streamlining AAV Vector-based Gene Therapy Development Through the Utilization of Manufacturing and Analytical Platform Approaches
Our ability to treat diseases previously untreatable through the delivery of adeno-associated virus (AAV)-based gene therapies has been a tremendous advancement in pharmaceutical development…
Thumbnail for Plenary Session 4 - Potency Assays for Gene Edited Products
Plenary Session 4 - Potency Assays for Gene Edited Products
Measurement of the biological activity is crucial for lot release, stability and any comparability exercise of all biological medicinal products…